Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma

被引:0
|
作者
Ouban, A
Dellis, J
Salup, R
Morgan, M
机构
[1] Univ S Florida, Coll Med, Dept Urol, Tampa, FL USA
[2] Univ S Florida, Coll Med, Dept Pathol, Tampa, FL USA
[3] James A Haley Vet Hosp, Tampa, FL 33612 USA
来源
关键词
Mdm2; p53; verrucous carcinoma; squamous cell carcinoma; penis;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Verrucous carcinoma (VC) of the penis is an uncommon squamous tumor that pursues a biologically indolent course. Unlike conventional squamous cell carcinoma (SCC) of the penis, pathogenic roles for human papillomavirus (HPV) infection and p53 mutation have not been reported in VC. We compared the immunohistochemical expression of Mdm2 and p53 in 7 cases of VC and 7 cases of SCC. The Mdm2 gene product preferentially labeled the perinuclear membrane in the granular layer of VC tumor cells, whereas SCC cases showed weak, focal, cytoplasmic staining for Mdm2. The mean labeling index for Mdm2 was higher in VC compared to SCC [79.3 (SE +/- 7.2) in VC vs 18.3 (SE +/- 2.4) in SCC, p <0.001]. In SCC cases, the normal surrounding skin showed mild granular-layer staining and dysplastic foci that failed to stain with Mdm2 antibody. Weak p53 immunolabeling was seen within nuclei of scattered tumor cells in the cases of VC, whereas the SCC cases showed strong nuclear staining of p53 throughout the tumors. The mean labeling index for p53 was lower in VC compared to SCC [24.8 (SE +/- 3.9) in VC vs 64.7 (SE +/- 9.0) in SCC, p <0.01]. In SCC cases, the normal surrounding skin showed moderate staining for p53, preferentially confined to the basal layer. Dysplastic foci in the cases of SCC showed increased p53 labeling. In summary, immunohistochemical analysis showed significantly different levels of expression of Mdm2 and p53 in penile VC vs SCC. Overexpression of the Mdm2 gene product may be important in the pathogenesis of VC. Since Mdm2 is a negative regulator of p53, overexpression of Mdm2 may explain why p53 is downregulated and, therefore, permissive to oncogenic transformation.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 50 条
  • [1] The expression of MDM2 and p53 protein breast carcinoma
    Hideshima, T
    Shinohara, T
    Baba, M
    Shirakusa, T
    ONCOLOGY REPORTS, 1997, 4 (02) : 297 - 300
  • [2] p53 and MDM2 expression in oral squamous cell carcinoma
    Matsumura, T
    Yoshihama, Y
    Kimura, T
    Shintani, S
    Alcalde, RE
    ONCOLOGY, 1996, 53 (04) : 308 - 312
  • [3] Immunohistochemical expression of Mdm2 and p53 in canine cutaneous mast cell tumours
    Wu, H
    Hayashi, T
    Inoue, M
    JOURNAL OF VETERINARY MEDICINE SERIES A-PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE, 2006, 53 (02): : 65 - 68
  • [4] MDM2 and p53 expression in ampullary adenocarcinomas
    Perysinakis, I.
    Leontara, V.
    Minaidou, E.
    Karambogias, C.
    Choreftaki, T.
    Zografos, G.
    Kouraklis, G.
    VIRCHOWS ARCHIV, 2015, 467 : S126 - S126
  • [5] MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma
    Ambros, RA
    Sheehan, CE
    Kallakury, BVS
    Ross, JS
    Malfetano, J
    Paunovich, E
    Figge, J
    MODERN PATHOLOGY, 1996, 9 (12) : 1165 - 1169
  • [6] MDM2 expression and p53 mutation in renal cell carcinoma.
    Warburton, HE
    Parsons, KF
    Linehan, WM
    Boyd, MT
    JOURNAL OF UROLOGY, 2005, 173 (04): : 104 - 104
  • [7] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [8] Immunohistochemical Comparison of the Expression of p53 and MDM2 Proteins in Ameloblastomas and Keratocystic Odontogenic Tumors
    Sharifi-Sistani, Noorieh
    Zartab, Hamed
    Babakoohi, Shahab
    Saghravanian, Nasrollah
    Jamshidi, Shokoofeh
    Esmaili, Habibollah
    Mohtasham, Nooshin
    Zamanzadeh, Maryam
    Abbaszadeh-Bidokhty, Hamid
    JOURNAL OF CRANIOFACIAL SURGERY, 2011, 22 (05) : 1652 - 1656
  • [9] MDM2与p53
    金晶
    刘耕陶
    癌症, 2001, (06) : 663 - 666
  • [10] MDM2 and BCL-2: to p53 or not to p53?
    Wang, Eunice S.
    BLOOD, 2023, 141 (11) : 1237 - 1238